In our cohort, patients with MSI‐H/wtBRAF tumors had the worst prognosis, in accordance with the randomized COIN trial.3 A recent study reports poor prognosis in mCRC patients with ALK, ROS1, and NTRK rearrangements in tumor, and these cases were associated with MSI‐H (48%) and were almost exclusively wtBRAF (96%).31 This might explain the particularly poor prognosis we see in this subpopulation, but the very limited number of patients in this group precludes firm conclusions and the results need verification in the larger studies. The gene discussed is ROS1; the disease is neoplasm.